Lupin announces Executive Leadership change

Global pharma major, Lupin Limited (Lupin) announced today changes to its executive team with Dr. Fabrice Egros assuming responsibilities for Global Corporate Development as President, Corporate Development and Growth Markets. Dr. Egros takes over the Corporate Development role from Alan Butcher departing from the Company on February 28, 2022. Dr. Egros will lead the development and execution of the Company's inorganic growth strategy, including mergers and acquisitions, business development, in-licensing arrangements, and related matters. He will continue to lead business in LATAM and Asia regions in this new role.

"We are very pleased to announce Fabrice taking over responsibilities for Corporate Development in addition to the Growth Markets business. With Fabrice's leadership and demonstrated success in growing Lupin's business through both organic and inorganic initiatives, we are well positioned to deliver on our growth aspirations. We thank Alan for his contribution to our organization and wish him well for the future," said Vinita Gupta, CEO, Lupin.

For the past over six years, Dr. Egros has played an integral role in Lupin, leading businesses across both Growth and Developed markets. His extensive cross-border experience as well as successful experience with acquisitions, divestitures, joint ventures and partnerships will be an asset to Lupin in this new role.

Shares of Lupin Limited was last trading in BSE at Rs. 752.15 as compared to the previous close of Rs. 761.05. The total number of shares traded during the day was 55259 in over 4001 trades.

The stock hit an intraday high of Rs. 754.25 and intraday low of 736.30. The net turnover during the day was Rs. 41335984.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 LeadershipChange CorporateDevelopment